Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03952299 · ClinicalTrials.gov registry record · Phase 3
Oxybutynin for Post-surgical Bladder Pain and Urgency
A Phase 3 study of Overactive Bladder Syndrome and Neuropathic Bladder, sponsored by University of California, Davis.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT03952299 is a Phase 3 study of Overactive Bladder Syndrome and Neuropathic Bladder that is actively recruiting participants, run by University of California, Davis. The registered enrollment target is 100 participants, below the 113-participant average among 11 other Overactive Bladder Syndrome trials with a reported enrollment target (12% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03952299, a Phase 3 study of Overactive Bladder Syndrome and Neuropathic Bladder, is actively recruiting participants, sponsored by University of California, Davis.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
Bladder pain and urgency are common after bladder surgery. The objective is to determine if transdermal administration is superior to oral administration in alleviating pain and urgency.
Conditions Studied
Interventions
- DRUG Oxybutynin Transdermal Patch
- DRUG Oral Oxybutynin
Study Locations (1)
California
- University of California Davis Medical Center (UCDMC) - Sacramento
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2021-09-01 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03952299
The ClinicalTrials.gov registry entry for NCT03952299 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 113-participant average among 11 other Overactive Bladder Syndrome trials with a reported enrollment target (12% lower). The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Overactive Bladder Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Oxybutynin Transdermal Patch is the first listed.
NCT03952299 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03952299 about?
NCT03952299 is a clinical study titled "Oxybutynin for Post-surgical Bladder Pain and Urgency". Bladder pain and urgency are common after bladder surgery. The objective is to determine if transdermal administration is superior to oral administration in alleviating pain and urgency.
What is the current status of trial NCT03952299?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 100 participants. The study started on 2021-09-01. Estimated completion is 2026-12-31.
What conditions does trial NCT03952299 study?
This clinical trial studies the following conditions: Overactive Bladder Syndrome, Neuropathic Bladder.
What interventions are being tested in trial NCT03952299?
The interventions under investigation include: Oxybutynin Transdermal Patch (DRUG), Oral Oxybutynin (DRUG).
Who is sponsoring clinical trial NCT03952299?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03952299 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Overactive Bladder Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP584) for the Treatment of Overactive Bladder Syndrome
COMPLETED · Phase 3
-
A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder.
COMPLETED · Phase 3
-
Testing MitoQ on Lower Urinary Tract Symptoms in Older Women With Metabolic Syndrome
RECRUITING · Phase 2
-
Improving Overactive Bladder Treatment Access and Adherence
RECRUITING · NA
-
Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms
RECRUITING · Phase 2
-
BTL Emsella Chair Versus Sham for the Treatment of Overactive Bladder
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.